About the company
NovoCure Ltd is a prominent player in the healthcare sector of the United States, specializing in the development, manufacture, and commercialization of innovative medical devices aimed at treating solid tumor cancers. The company's primary focus revolves around the advancement and application of Tumor Treating Fields (TTFields) technology. TTFields is a groundbreaking therapeutic approach that utilizes low-intensity, alternating electric fields to disrupt cell division and inhibit tumor growth. NovoCure's flagship products, Optune and Optune Lua, harness the power of TTFields to provide non-invasive treatment options for patients suffering from various types of solid tumors. One of the key areas of NovoCure's research and development efforts lies in ovarian cancer. Currently, this devastating disease often presents limited treatment options and poor prognoses. NovoCure is dedicated to improving outcomes for ovarian cancer patients by exploring the potential of TTFields therapy as an adjunctive treatment to traditional therapies. By disrupting the division of cancer cells, TTFields have shown promise in suppressing tumor growth and increasing overall survival rates for ovarian cancer patients. Another area of focus for NovoCure is pancreatic cancer, a particularly aggressive and challenging form of cancer. With limited treatment options available, NovoCure aims to leverage the power of TTFields to improve the lives of pancreatic cancer patients. By integrating TTFields therapy into standard treatments such as chemotherapy, NovoCure seeks to enhance the efficacy and overall outcomes for patients battling this devastating disease. Non-Small Cell Lung Cancer (NSCLC) is another solid tumor cancer type that NovoCure aims to address with its TTFields technology. NSCLC is the most common form of lung cancer and is notorious for its resistance to standard treatments. NovoCure's clinical studies in this field have shown encouraging results, demonstrating the potential of TTFields therapy to disrupt tumor cell division and impede disease progression in NSCLC patients. By offering a non-invasive and targeted treatment option, NovoCure hopes to provide lung cancer patients with improved outcomes and a potentially higher quality of life. Brain metastasis, the spread of cancer to the brain from other parts of the body, poses a formidable challenge in cancer treatment. NovoCure recognizes the urgent need for effective therapeutic options for patients battling this devastating condition. With ongoing research efforts and clinical trials, NovoCure aims to position TTFields therapy as a viable treatment modality for brain metastasis. By specifically targeting tumor cells in the brain with TTFields, NovoCure aspires to enhance patient survival rates and improve their overall well-being. NovoCure's products consist of two primary components: the electric field generator and the arrays, along with other related accessories. The electric field generator delivers precisely calibrated and controlled electric fields, while the arrays and accessories are designed to be user-friendly, allowing patients to easily integrate TTFields therapy into their daily lives. While NovoCure derives a significant portion of its revenues from the United States, the company has also been making strides in expanding its global footprint. Recognizing the immense potential and demand for TTFields therapy worldwide, NovoCure is actively exploring opportunities to introduce its innovative medical devices and treatment protocols in other markets. With a commitment to improving patient outcomes, NovoCure continues to lead the way in the development and commercialization of advanced solutions for the treatment of solid tumor cancers.
Website: https://www.novocure.com
Data updated: June 2, 2026
